Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 561 - 570 of 763 studies

Safety and Efficacy of Aneurysms Treated with Endovascular Devices (SEATED)

Cardiovascular

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Orticumab in Participants with Prior Myocardial Infarction who have Elevated Coronary Inflammation Based on Fat Attenuation Index (FAI) Score Assessed by Coronary Computed Tomography Angiography (CCTA) (FORTIFY)

Predicting Long-Term Success and Identifying Optimal Treatment Strategies for Idiopathic Toe Walking

Clinical Management and Short-Term Outcomes of Neonates Born at 22 Weeks in UK Neonatal Intensive Care Units

Observational multi-centre study comparing fasciculation frequency detected using motor unit MRI (MUMRI) across scanner make and magnet strength.

Cancer and neoplasms

NX-5948-201 - A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton’s Tyrosine Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2 Inhibitor (BCL-2i)

Neurological

Phase 3 Study of the Efficacy and Safety of ION582 in Children and Adults with Angelman Syndrome (ION582-CS2 (REVEAL))

Inflammatory and immune system

PAXIS: A randomized, double-blind, placebo-controlled dose-finding phase 2 study (Part 1) followed by an open-label period (Part 2) to assess the efficacy and safety of pacritinib in patients with VEXAS syndrome (PAXIS)

Cancer and neoplasms

BCA101X301 - A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1- positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (BCA101X301)

Cancer and neoplasms

IAM1363-01 - A Phase 1/1b Study of IAM1363 in Participants with Advanced Cancers Harboring HER2 Alterations